Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Defibrillators”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 829 records · Page 46Linked to original sources
PubMed1993

[Low energy cardioversion with the implantable cardioversion defibrillator devices for treatment of ventricular tachycardia and ventricular fibrillation].

Programmable implantable cardioverter-defibrillators (ICD) with low energy capabilities for the treatment of ventricular tachycardia were introduced to increase patients acceptance and lengthen battery life. However, no data about efficacy and safety of low energy cardioversion with subsequent defibrillation in ventricular tachycardia and fibrillation are available. Nineteen of 42 patients with documented or inducible ventricular tachycardia before ICD implantation were studied. In all patients the effectiveness of low-energy cardioversion (< or = 4 joules) with subsequent high-energy defibrillation was evaluated in monomorphic ventricular tachycardia and/or ventricular fibrillation. During predischarge programmed stimulation in 13/19 patients, a total of 32 monomorphic ventricular tachycardias occurred, and in only six patients could ventricular fibrillation be induced. A tachycardia-related efficacy of 69% and patient-related efficacy of 46% of the low-energy cardioversion < or = 4 joules was observed. Ten tachycardias were accelerated to ventricular fibrillation or remained unchanged (n = 2). The second shock (energy > 17 joules) terminated seven arrhythmias, whereas a third (30 joules) shock or an external defibrillation (n = 2) was necessary for termination of the remaining three arrhythmias. After induction of ventricular fibrillation as the primary arrhythmia, the first (low-energy) shock terminated 2/16 episodes, whereas the second (high-energy) shock reverted ventricular fibrillation in 11/16 episodes. In one patient, a second high energy shock and in two patients external defibrillation was necessary for conversion of ventricular fibrillation. In one patient, an increase of the defibrillation threshold induced by amiodarone could be identified.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1993

Clinical experience with the transvenous Medtronic Pacer Cardioverter Defibrillator (PCD) System.

We review our experience with the transvenous Medtronic Pacer Cardioverter Defibrillator System (Model 7217B), a multifunction implantable pacer defibrillator combined with a transvenous lead system (Transvene). From April 1991 to October 1992, we implanted this device in 19 consecutive patients (11 men and 8 women; average age, 56.5 years). Nine patients (47.4%), 5 with coronary artery disease and 4 with dilated cardiomyopathy, had an ejection fraction of < 30%. The average operative time was 129 minutes. In 18 patients (94.7%), the transvenous lead system provided effective sensing, pacing, and defibrillation during intraoperative testing. In each of these cases, the defibrillation threshold was less than 18 J. In 1 patient (5.3%), it was necessary to switch to epicardial leads, which were implanted through a left thoracotomy. All patients were extubated in the recovery room. The average hospital stay was 8 days. There was no early mortality or morbidity. During a maximum follow-up period of 17 months (mean, 9.2 months), no sudden death occurred. The implantable system terminated 245 ventricular tachycardia episodes in 14 patients (73.7%) and 82 ventricular fibrillation episodes in 13 patients (68.4%). Two hundred eleven (86.1%) of the ventricular tachycardia episodes were resolved by antitachycardia pacing alone. In 2 patients (10.5%), the caval electrode became dislocated; repositioning of the electrode was followed by repeat defibrillation threshold evaluation. Our experience shows that the transvenous Medtronic Pacer Cardioverter Defibrillator System provides safe, effective treatment of ventricular tachyarrhythmias. Because the perioperative mortality and morbidity are extremely low, use of this device may be particularly beneficial in patients with a high operative risk. Moreover, the lower number of unpleasant therapeutic shocks should increase patient a acceptance of the device.

Adult↗
PubMed1996

[Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].

The usefulness and problems of implantable cardioverter defibrillators (ICD) were examined in patients with reduced heart function. Of 36 patients who received ICD for refractory ventricular tachycardia (VT) or ventricular fibrillation (VF), VT and/or VF was associated with underlying heart disease in 26 patients, and VF without underlying heart disease in 10. Of the former 26 patients, 13 with left ventricular ejection fraction (LVEF) of less than 30% were assigned to group A, 13 with LVEF of greater than 30% to group B, and the other 10 with idiopathic VF to group C. Intraoperative death, cardiac death due to heart failure, sudden death, functional status of the ICD, exacerbation of heart failure symptoms and complications were compared between the three groups. There were no intraoperative deaths in any of the groups. During the median follow-up period of 36 +/- 22 months, there was only one sudden death in group A. There were no significant differences between the three groups. There were five cardiac deaths in group A, but none in groups B or C. The cardiac death-free rates 12, 24, and 36 months after implantation in group A were 83%, 60% and 50%, respectively. These values significantly differed from those in groups B and C (p < 0.05). The number of patients who received defibrillation therapy was higher in group A (p < 0.05). Defibrillation therapy was administered earlier in group A than in groups B and C (p < 0.05). The incidence of exacerbation of heart failure after implantation was 69%, 23% and 0% in groups A, B, and C, respectively. In group A, defibrillation therapy was administered in all patients with exacerbation of heart failure. The administration of defibrillation therapy significantly differed from that in patients without exacerbation of heart failure (p < 0.05). Exacerbation of heart failure during the postoperative acute stage occurred in both patients in group A in whom an epicardial lead system was used, but not in the four patients in group B or five in group C (p < 0.05). There were no differences in the incidence of other complications between the three groups. In group A, patients with reduced heart function, ICD greatly decreased the risk of sudden death. However, heart failure mortality remained high. Therefore, ICD may have limitations for improved prognosis. In group A patients, defibrillation therapy was administered in all patients with exacerbation of heart failure or death due to heart failure. In patients with reduced heart function, treatment for heart failure and prophylaxis of VT and/or VF should be administered.

Adult↗
PubMed1998

Specific considerations with the automatic implantable atrial defibrillator.

INTRODUCTION: Internal atrial defibrillation has been evaluated as an alternative approach to the external technique for more than two decades. Previous studies in animals and humans have shown that internal atrial defibrillation is feasible with relatively low energies. The promising results achieved with internal atrial defibrillation have facilitated the development of an implantable atrial defibrillator (IAD). METHODS AND RESULTS: For any new therapy, it is imperative to demonstrate safety, efficacy, tolerability with improvement in quality of life, and cost-effectiveness compared with therapeutic options already available. Maintenance of sinus rhythm or prolonged duration in arrhythmia-free intervals should be demonstrated clearly with an IAD. Initial clinical experience with the Metrix system indicates stable atrial defibrillation thresholds, appropriate R wave synchronization markers, no shock-induced ventricular proarrhythmia, and excellent detection of atrial fibrillation (AF) with a specificity of 100%. Ventricular proarrhythmia has not been reported for correctly R wave synchronized low-energy shocks when closely coupled to RR intervals, and long-short cycles are avoided. CONCLUSION: Preliminary experience with the Metrix system suggests that the IAD may offer a therapeutic alternative for a subgroup of patients with drug-refractory, symptomatic, long-lasting, and infrequent episodes of AF. Further efforts must be undertaken to reduce the patient discomfort associated with internal atrial defibrillation in an attempt to make this new therapy acceptable to a larger patient population with AF.

Algorithms↗
PubMed1998

[The concurrent implantation of a last-generation automatic defibrillator and a 2-chamber pacemaker].

BACKGROUND: Potentially lethal interactions between concomitantly implanted pacemaker and automatic first-generation cardioverter-defibrillator have been reported. We therefore evaluated the reliability and safety of simultaneous implantation of dual-chamber pacemakers with a fourth generation cardioverter-defibrillator incorporating an improved arrhythmia detection system. METHODS: Concomitant implantation of an automatic cardioverter defibrillator and a dual-chamber pacemaker was performed in four patients for malignant tachyarrhythmias and symptomatic bradycardia. Two Jewel 7219C and two Micro Jewel 7223 (Medtronic Inc.) implantable cardioverter defibrillators were connected to an endocardial lead (Medtronic Mod. 6936). In 2 patients with a previously implanted cardioverter-defibrillator, the pacemaker was connected to bipolar atrial and ventricular leads. In the 2 patients who already had a dual-chamber pacemaker, the unipolar pacing leads implanted previously were used. At the time of implantation of the second device, interaction testing was performed evaluating ventricular fibrillation detection during high-output asynchronous pacing. Testing for malfunctions, reprogramming or variations of pacing thresholds of the pacemakers after electric shocks was also carried out. Moreover, intracavitary signals, stimulation thresholds and electrical therapies delivered were evaluated during follow-up. RESULTS: During interaction testing, induced ventricular fibrillation was detected, with no delay, in 4/4 cases (100%). After a mean follow-up of 6.3 +/- 5 months (range 2-13), 5 shocks for ventricular fibrillation, 10 shocks for fast ventricular tachycardia and 72 antitachycardia pacings were delivered. All these electrical therapies were considered appropriate. No symptomatic sustained tachyarrhythmia remained undetected. CONCLUSIONS: These data suggest that concomitant implantation of a fourth-generation automatic cardioverter-defibrillator and a dual-chamber pacemaker using either unipolar or bipolar leads can be performed safely. Extreme caution and rigorous interactions testing is nevertheless advised when considering this device combination.

Aged↗
PubMed1993

Impact of first-responder defibrillation in an urban emergency medical services system.

OBJECTIVE: To evaluate the impact of adding first-responder defibrillation by fire-fighters to an existing advanced life-support emergency medical services system. DESIGN: Nonrandomized, controlled clinical trial with periodic crossover. SETTING: Memphis, Tenn, a city of 610,337 people, which is served by a fire department-based emergency medical services system. All city ambulances provide advanced life support. PATIENTS: Adult victims of out-of-hospital cardiac arrest due to heart disease. INTERVENTION: Twenty of 40 participating engine companies were equipped with an automated external defibrillator and ordered to apply it immediately in all cases of cardiac arrest. The other 20 companies were ordered to start cardiopulmonary resuscitation (CPR) immediately and wait for paramedics to arrive. Every 75 days, group roles were reversed. Care otherwise proceeded according to 1986 American Heart Association guidelines. MAIN OUTCOME MEASURES: Return of spontaneous circulation in the field, survival to hospital admission, survival to hospital discharge, and neurological status at discharge. RESULTS: During the 39-month study interval, 879 patients were treated by a project engine company. Four hundred thirty-one (49%) of these were found in ventricular fibrillation. Bystander CPR was started in only 12% of cases. Overall, firefighters reached the scene a mean of 2.5 minutes faster than simultaneously dispatched paramedics. Although our automated external defibrillators proved to be reliable and efficacious for terminating ventricular fibrillation and pulseless ventricular tachycardia, patients treated by an automated external defibrillator-equipped engine company were no more likely than CPR-treated controls to be resuscitated (32% vs 34%, respectively), to survive to hospital admission (31% vs 29%), or to survive to hospital discharge (14% vs 10%). Neurological outcomes were also similar in the two treatment groups. CONCLUSIONS: In a fast-response, urban emergency medical services system served by paramedics, the impact of adding first-responder defibrillation appears to be small. Early defibrillation alone cannot overcome low community rates of bystander CPR. Careful attention to every link in the "chain of survival" is needed to achieve optimal rates of survival after cardiac arrest.

Aged↗
PubMed1999

Improved out-of-hospital cardiac arrest survival through the inexpensive optimization of an existing defibrillation program: OPALS study phase II. Ontario Prehospital Advanced Life Support.

CONTEXT: Survival rates for out-of-hospital cardiac arrest are low; published survival rates in Ontario are only 2.5%. This study represents phase II of the Ontario Prehospital Advanced Life Support (OPALS) study, which is designed to systematically evaluate the effectiveness and efficiency of various prehospital interventions for patients with cardiac arrest, trauma, and critical illnesses. OBJECTIVE: To assess the impact on out-of-hospital cardiac arrest survival of the implementation of a rapid defibrillation program in a large multicenter emergency medical services (EMS) system with existing basic life support and defibrillation (BLS-D) level of care. DESIGN: Controlled clinical trial comparing survival for 36 months before (phase I) and 12 months after (phase II) system optimization. SETTING: Nineteen urban and suburban Ontario communities (populations ranging from 16 000 to 750 000 [total, 2.7 million]). PATIENTS: All patients who had out-of-hospital cardiac arrest in the study communities for whom resuscitation was attempted by emergency responders. INTERVENTIONS: Study communities optimized their EMS systems to achieve the target response interval from when a call was received until a vehicle stopped with a defibrillator of 8 minutes or less for 90% of cardiac arrest cases. Working both locally and provincially, communities implemented multiple measures, including defibrillation by firefighters, base paging, tiered response agreements with fire departments, continuous quality improvement for response intervals, and province-wide revision and implementation of standard dispatch policies. All response times were obtained from a central dispatch system. MAIN OUTCOME MEASURE: Survival to hospital discharge. RESULTS: The 4690 cardiac arrest patients studied in phase I and the 1641 in phase II were similar for all clinical and demographic characteristics, including age, sex, witnessed status, rhythm, and receipt of bystander cardiopulmonary resuscitation. The proportion of cases meeting the 8-minute response criterion improved (76.7% vs 92.5%; P<.001) as did most median response intervals. Overall survival to hospital discharge for all rhythm groups combined improved from 3.9% to 5.2 % (P = .03). The 33% relative increase in survival represents an additional 21 lives saved each year in the study communities (approximately 1 life per 120000 residents). The charges were estimated to be US $46900 per life saved for establishing the rapid defibrillation program and US $2400 per life saved annually for maintaining the program. CONCLUSION: An inexpensive, multifaceted system optimization approach to rapid defibrillation can lead to significant improvements in survival after cardiac arrest in a large BLS-D EMS system.

Aged↗
PubMed2005

Impedance-gradient electrode reduces skin irritation induced by transthoracic defibrillation.

A new type of disposable external defibrillation electrode has been developed to reduce the skin irritation commonly associated with defibrillation and synchronised cardioversion. This design employs an impedance gradient to reduce the proportion of current delivered to the electrode periphery. The temperature distribution under the new electrode was compared with that of four other types of commercially available electrodes after repeated high-energy biphasic defibrillation discharges to domestic swine. Skin temperature distributions were acquired using non-invasive thermography. Measurements of the maximum temperature rise at each electrode site, taken 3.6s after the fifth defibrillation discharge, demonstrated that the new impedance-gradient electrode produced 50-60% less skin heating than two of the three uniform-impedance electrode designs. Histological examination of erythematous sites excised 24 h after defibrillation quantified the associated skin damage using a scoring protocol developed for this study. In contrast to previous studies, histological examinations demonstrated second-degree skin burns following defibrillation. The new electrode design, however, induced 44-46% less skin damage than two of the traditional uniform-impedance electrodes.

Animals↗
PubMed1987

Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements.

Amiodarone is commonly used with the automatic implantable defibrillator to treat recurrent ventricular tachyarrhythmias. The effects of acute intravenous and chronic oral amiodarone on the energy requirements for successful defibrillation were evaluated in 12 dogs chronically instrumented with right atrial spring and left ventricular patch defibrillation electrodes. Multiple shocks of varying energy were applied in balanced random order to construct curves of percent successful defibrillation vs energy (DF curves) on each test day. Dogs were studied on days 1, 11, 18, 25, and 32. On day 11, DF curves were determined before and after infusing saline (n = 6) or amiodarone (n = 6), 10 mg/kg loading and 0.33 mg/kg/min maintenance doses. Dogs administered intravenous amiodarone were continued on oral drug (300 mg twice daily) for the remainder of the study. Data were analyzed by logistic regression and the energy required for 50% (E50) and 80% (E80) successful defibrillation were compared. Differences between controls and animals receiving chronic oral amiodarone were not significant on any day. After acute intravenous infusion, dogs given amiodarone had a 21.7 +/- 12.8% decrease in E50 (p less than 0.01) and a 19.7 +/- 17.8% decrease in E80 (p less than 0.05), while controls had an 11.4 +/- 30.5% increase (p = NS) in E50 and 6.30 +/- 30.5 increase in E80 (p = NS). It is concluded that the energy required for successful defibrillation is decreased by acute intravenous amiodarone, while chronic oral administration has no significant effect.

Administration, Oral↗
PubMed1988

Absence of significant postdefibrillation bradyarrhythmias in patients with automatic implantable defibrillators.

Because postdefibrillation bradycardia or asystole is of clinical concern in patients with implanted automatic cardioverter defibrillators, we analyzed the cardiac rhythm after 157 intraoperative defibrillations in 50 patients undergoing implantation of the device. Factors that could influence the heart rhythm immediately after defibrillation were also analyzed. The postdefibrillation heart rate and the duration of postdefibrillation asystole did not correlate with age, conduction abnormalities, type or duration of arrhythmia before defibrillation, delivered energy, lead system, or left ventricular ejection fraction, but they did correlate with the resting preoperative heart rate and the concomitant performance of coronary artery bypass surgery at the time of defibrillator implantation. Temporary pacing (for prolonged asystole) was required in only two patients, both of whom had also undergone bypass surgery. Fourteen patients being treated with amiodarone had slower resting and postdefibrillation heart rates, but the mean duration of posdefibrillation asystole was similar to that seen in patients not receiving any antiarrhythmic medication. On follow-up, 25 monitored and 178 unmonitored automatic defibrillator discharges occurred in 24 patients, without evidence of symptomatic postdefibrillation bradyarrhythmias. Thus significant postdefibrillation bradyarrhythmias were uncommon, but when such a propensity existed it could not be predicted reliably on clinical grounds alone.

Adult↗
PubMed1989

Sequential pulse internal defibrillation: is there an advantage to "switched" current pathways?

Sequential pulse internal defibrillation delivered via orthogonal current pathways has been postulated to improve defibrillation efficacy. The efficacy of twin truncated exponential sequential shocks was compared in four different defibrillation electrode configurations in six pentobarbital-anesthetized, open-chest dogs. Lead systems consisted of the conventional single current pathway spring-patch and patch-patch electrode configurations, as well as a multiple patch lead configuration, which utilized either a single (multiple patch-unswitched) or two different (multiple patch-switched) current pathways. Curves of percent successful defibrillation versus initial voltage and energy were constructed and the data were analyzed by logistic regression. The energy and initial voltage required for 50% successful defibrillation (E50 and V50, respectively) for each lead system were then compared. The E50 for the multiple patch-unswitched and switched lead systems (4.3 +/- 1.5 J and 4.6 +/- 1.7 J, respectively) were significantly lower than for the spring-patch (9.0 +/- 3.1 J; p less than .005) and patch-patch (6.6 +/- 1.2 J; p less than .005) lead systems. In addition, the V50 for the multiple patch-unswitched lead configuration (270.6 +/- 48.4 V) was significantly lower than that of all other lead systems (p less than .005). Therefore lead configurations utilizing multiple patch electrodes improve defibrillation efficacy over conventional lead systems, but there is no advantage to "switched" current pathways.

Animals↗
PubMed1990

Efficacy and safety of monophasic and biphasic waveform shocks using a braided endocardial defibrillation lead system.

Endocardial lead systems for implantable cardioverter-defibrillators utilize large (12F) rigid catheters with spring defibrillation electrodes, and lead system failure has been observed during long-term implant. We evaluated a novel flexible 8F braided electrode catheter for pacing and defibrillation in canine experiments. Active fixation and pacing were accomplished using a screw-in distal electrode, and defibrillation pulses were delivered through a braided electrode. Two braided electrode catheters were positioned in the right ventricular apex (6 cm2) and in the superior vena cava-right atrial junction (5 cm2), respectively. An elliptical 13 cm2 surface area patch electrode was positioned along the left lateral cardiac border. Ventricular fibrillation (VF) was induced and monophasic and asymmetric biphasic shocks (leading voltages 260 to 1000 V) were delivered via dual and triple electrode configurations in each animal using a prospective randomized crossover study design. Mean right ventricular pacing threshold was 0.5 +/- 0.2 mA, with a mean electrogram amplitude of 11.1 +/- 2.8 mV during sinus rhythm prior to fibrillation and defibrillation. Two hundred seven VF inductions (mean 30 +/- 4 per animal) were analyzed. The mean defibrillation threshold could be reduced to 8.0 +/- 3.2 joules with biphasic shocks from 12.9 +/- 5.1 joules obtained for monophasic shocks using a dual electrode system (p less than 0.004). Mean shock leading voltage was correspondingly reduced to 488 +/- 100 V from 691 +/- 154 V (p less than 0.0006).(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1993

Biphasic versus sequential pulse defibrillation: a direct comparison in humans.

It has been demonstrated recently that both biphasic and sequential pulse defibrillation shocks are superior to monophasic defibrillation shocks in animals and humans. There is little information directly comparing these two waveforms when pulse characteristics, subjects, and total electrode surface areas are kept constant. We determined the defibrillation threshold intraoperatively in 12 patients undergoing arrhythmia surgery, with the use of two or three patch electrodes (Medtronic 6891 and 6892), while keeping the electrode surface area constant. Patients were randomized in a crossover design for determinations of defibrillation threshold by means of biphasic and sequential pulse shocks. Leading-edge delivered current and delivered energy were significantly lower with sequential pulse shocks than with biphasic shocks (delivered energy means +/- SEM 3.6 +/- 0.7 joules vs 5.5 +/- 0.9 joules, respectively). We conclude that sequential pulse defibrillation with three defibrillating electrodes provides an important current delivery system not matched by biphasic shocks with two electrodes when subjects, waveform characteristics, and total electrode surface areas are kept constant.

Adult↗
PubMed1994

Pronounced increase in defibrillation threshold associated with pacing-induced cardiomyopathy in the dog.

Progressive changes in myopathology after implantation of an automatic defibrillator could compromise device efficacy. The influence of heart failure development on the defibrillation threshold was evaluated by means of a rapid ventricular pacing model of heart failure in dogs. After transvenous pacemaker lead implantation, adult mongrel dogs were randomly assigned to either the control (n = 7) or rapidly paced group (240 beats/min, n = 6). Seventeen days after implantation, triplicate determinations of the defibrillation threshold were made with three epicardial electrodes. The average defibrillation threshold was four times higher in the rapidly paced group, 13.3 +/- 2.0 joules (mean +/- SEM), than in the control group, 3.3 +/- 0.7 joules (p < 0.01), and was significantly correlated with ventricular weight (r = 0.70, p < 0.01). Both defibrillation threshold energy per gram of ventricle and ventricular weight corrected for body weight were significantly higher in rapidly paced dogs compared with control dogs. It was concluded that myocardial hypertrophy and heart failure may profoundly increase defibrillation energy requirements.

Animals↗
PubMed1991

A cellular transtelephonic defibrillator for management of cardiac arrest outside the hospital.

A cellular transtelephonic defibrillator facilitates early defibrillation in remote areas and involves electrocardiographic diagnosis and defibrillation control by a physician remote from but in voice contact with the patient-unit operator. The patient unit contains a microprocessor, microphone, defibrillator, electrocardiogram/defibrillator electrode pads and cellular telephone. Activation of the patient-unit initiates automatic dialing and contact with the remotely sited base station within 35 to 50 seconds. The physician at the base station identifies the rhythm and controls defibrillator charging and discharge. The minimal interaction required between the system and the local operator makes it suitable for use by minimally trained first responders. The cellular transtelephonic defibrillator has been tested in 211 calls responded to by a physician-manned mobile coronary care unit over distances up to 15 miles in an urban area. Satisfactory electrocardiographic transmission and voice communication were established in 172 of 211 calls (81.5%). In 39 (18.5%), connection with the base station either could not be established or maintained mainly because of geographic location or battery failure. One hundred direct current shocks of 50 to 360 J were effectively administered to 22 patients with 48 episodes of ventricular fibrillation or ventricular tachycardia with successful correction of 46 of 48 episodes using 1 to 4 shocks per episode. Widespread distribution of such devices could improve survival in patients with cardiac arrest outside the hospital.

Ambulances↗
PubMed1980

Criteria of efficiency and safety of the defibrillating impulse.

The effectiveness and safety of the defibrillating effect of a bipolar impulse produced by a Soviet DK1-01 defibrillator and the Monopolar impulse Ed-Mark have been tested in 14 experiments on the anaesthetized dogs. A quantitative criterion to compare the safety of different defibrillators and an electro-therapeutic index of the defibrillating action are being suggested. It is defined as the ratio of the thresholds of energy in joules causing lesions to that causing defibrillation. In the above experiments the mean value of this therapeutic index was 1.59 +/- 1.41 for the Ed-Mark impulse and 4.32 +/- 2.78 for the defibrillator DK1-01 impulse. The difference of the mean values was statistically significant (P = 0.02).

Animals↗
PubMed1984

The epidemiology of defibrillation in a medical school complex.

Defibrillation is the definitive treatment for ventricular fibrillation (VF). Participation of physicians, paramedical personnel and lay people in cardiopulmonary resuscitation has significantly increased the survival from ventricular fibrillation. The number of defibrillators has increased and their primary placement within the hospital and community has changed. We studied the location, age, history, characteristics and maintenance of every defibrillator (n = 190) within a three hospital, medical school complex. Most defibrillators had been acquired recently but some dated from 1967. More than 85% were plug-in, non-portable. The government hospital had the lowest ratio of defibrillators to beds, but its maintenance, reliability and records were ths most efficient. We conclude that the increase in the number of defibrillators and its modernization reflects their importance, and that the type of hospital determines the age, type of machine, maintenance, and quantity.

Electric Countershock↗
PubMed1993

Performance of an established system of first responder out-of-hospital defibrillation. The results of the second year of the Heartstart Scotland Project in the 'Utstein Style'.

The Heartstart Scotland project for out-of-hospital defibrillation covers the whole of Scotland, a population of approximately 5,102,400 (14.9% > 65 years, 48.3% male). All 395 ambulances in Scotland have been equipped with an automated external defibrillator and crews are trained in basic cardiopulmonary resuscitation and defibrillator use (EMT-D). Between 1 May 1990 and 30 April 1991 a total of 1700 cardiac arrests was reported by the ambulance service. Of the 1676 arrests which we could trace, 63% were witnessed. A total of 1383 (83%) of all patients were declared dead on arrival at hospital or in the emergency department, 119 (7%) died in hospital and 174 (10%) were discharged alive. Of the 174 survivors, 87% were conscious and normal at discharge, 9% had moderate residual disability and 2% severe disability. Survival of patients discharged alive from hospital was 85% at 1 year. Defibrillation was undertaken in 71% of the reported cardiac arrests. Survival of bystander witnessed arrests was increased from 7 to 15% with bystander CPR (P < 0.005). If the cardiac arrest was witnessed by the ambulance crew and required defibrillation, survival to discharge was 39%. Of bystander witnessed arrests reached while still in VF (n = 643), 11% were discharged alive. Patients who were defibrillated within 4 min of arrest had a 43% survival rate to hospital discharge.

Cardiopulmonary Resuscitation↗